Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Neoplasm Metastasis 1

Interventions

Topotecan 10Etoposide 7Specimen Handling 6berzosertib 5Cisplatin 5Biopsy 5sargramostim 4Platinum 4Magnetic Resonance Spectroscopy 4Irinotecan 4Carboplatin 4trioctyl phosphine oxide 3X-Rays 3Paclitaxel 3Nivolumab 31,2-diaminocyclohexaneplatinum II citrate 3veliparib 2romidepsin 2olaparib 2cabozantinib 2aldesleukin 2Tomography, X-Ray Computed 2Temozolomide 2Sunitinib 2PM 01183 2Electrocardiography 2Depsipeptides 2Decitabine 2Cyclophosphamide 2Budesonide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Small Cell Lung Carcinoma × vistusertib × Clear all
NCT03366103 2023-10-17

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Terminated
15 enrolled 14 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡